Relentless Health Value

Today I speak with James Nicholls about the Fitzroy Health study looking at 1400 health system health care services deals. We discuss what worked and what didn’t work, and James gives us the main takeaways from the study.

You can learn more about the study by contacting James at jnicholls@fitzroyhealth.com or visiting fitzroyhealth.com.

James is the founder and managing director of Fitzroy Health, a leading international health care investment and commercialization firm. He has served as an executive, entrepreneur, and investor in health care firms across numerous international markets. James sits on the boards of RJ Health Systems, DosedDaily, Salute Safety, and Flex Health. He was awarded Entrepreneur of the Year at The Wharton School 2009 WEC Expo and has been profiled by the Financial Times. James holds a BA from The University of Melbourne and an MBA from Columbia Business School.

00:46 Fitzroy Health’s findings in their study of health care deals in health systems.
01:16 Developing an understanding of what has been working and what hasn’t been working in health investments.
01:34 Three letters of value creation.
03:15 The lack of success in health care technology innovations and why.
04:23 “Where there are disruptive approaches to traditional operational models … that’s where health systems have proven to have the best opportunities.”
04:37 The three categories: licensing drugs and devices, licensing new technologies, creating disruptive models.
05:15 What exactly the Fitzroy Health study was focusing on.
06:40 LP—limited partner, or investor in a private equity fund.
07:15 ONcore Value.

You can learn more about the study by contacting James at jnicholls@fitzroyhealth.com or visiting fitzroyhealth.com.